Display options
Cite
Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-92doi: 10.1016/j.jalz.2011.03.003.
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., & Phelps, C. H. (2011). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association, 7(3), 280-92. https://doi.org/10.1016/j.jalz.2011.03.003
Sperling, Reisa A, et al. "Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease." Alzheimer's & dementia : the journal of the Alzheimer's Association vol. 7,3 (2011): 280-92. doi: https://doi.org/10.1016/j.jalz.2011.03.003
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):280-92. doi: 10.1016/j.jalz.2011.03.003. Epub 2011 Apr 21. PMID: 21514248; PMCID: PMC3220946.
Copy Download .nbib Format: NLM
Share it on

Alzheimers Dement. 2011 May;7(3):280-92. doi: 10.1016/j.jalz.2011.03.003. Epub 2011 Apr 21.

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association

Reisa A Sperling, Paul S Aisen, Laurel A Beckett, David A Bennett, Suzanne Craft, Anne M Fagan, Takeshi Iwatsubo, Clifford R Jack, Jeffrey Kaye, Thomas J Montine, Denise C Park, Eric M Reiman, Christopher C Rowe, Eric Siemers, Yaakov Stern, Kristine Yaffe, Maria C Carrillo, Bill Thies, Marcelle Morrison-Bogorad, Molly V Wagster, Creighton H Phelps

Affiliations

  1. Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. [email protected]

PMID: 21514248 PMCID: PMC3220946 DOI: 10.1016/j.jalz.2011.03.003

Abstract

The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long "preclinical" phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from "normal" cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease-modifying therapies may be most efficacious.

Copyright © 2011. Published by Elsevier Inc.

References

  1. Arch Gen Psychiatry. 2006 Feb;63(2):153-60 - PubMed
  2. Arch Neurol. 2008 Nov;65(11):1509-17 - PubMed
  3. Neurobiol Aging. 2010 Aug;31(8):1275-83 - PubMed
  4. Ann Neurol. 2009 Apr;65(4):403-13 - PubMed
  5. Neurology. 2010 Mar 9;74(10):807-15 - PubMed
  6. PLoS One. 2010 Sep 23;5(9):e12853 - PubMed
  7. Arch Neurol. 2007 Mar;64(3):343-9 - PubMed
  8. Neurology. 2010 Jul 13;75(2):143-51 - PubMed
  9. Neuropsychologia. 2008;46(6):1688-97 - PubMed
  10. Neurology. 2009 Jun 9;72(23):2029-35 - PubMed
  11. Brain. 2011 Mar;134(Pt 3):798-807 - PubMed
  12. Ann Neurol. 2010 Mar;67(3):353-64 - PubMed
  13. Acta Neuropathol. 1991;82(4):239-59 - PubMed
  14. Science. 2002 Oct 25;298(5594):789-91 - PubMed
  15. Am J Geriatr Psychiatry. 2007 May;15(5):365-75 - PubMed
  16. J Neurosci. 2010 Nov 10;30(45):14946-54 - PubMed
  17. Neurology. 2005 Jul 26;65(2):323-5 - PubMed
  18. Neuroimage. 2011 Feb 1;54(3):1887-95 - PubMed
  19. Neurology. 2010 Sep 14;75(11):990-6 - PubMed
  20. Alzheimers Dement. 2011 May;7(3):270-9 - PubMed
  21. Neurology. 2008 Sep 16;71(12):903-10 - PubMed
  22. Neurology. 2007 Aug 14;69(7):631-9 - PubMed
  23. Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6820-5 - PubMed
  24. JAMA. 2011 Jan 19;305(3):261-6 - PubMed
  25. Ann Neurol. 2006 Mar;59(3):512-9 - PubMed
  26. Brain. 2008 Mar;131(Pt 3):665-80 - PubMed
  27. Alzheimers Dement. 2011 May;7(3):257-62 - PubMed
  28. Arch Neurol. 2009 Mar;66(3):300-5 - PubMed
  29. Arch Neurol. 2009 Dec;66(12):1469-75 - PubMed
  30. Neuromolecular Med. 2011 Mar;13(1):37-43 - PubMed
  31. J Int Neuropsychol Soc. 2008 Mar;14(2):192-8 - PubMed
  32. J Neurosci. 2010 Dec 15;30(50):16755-62 - PubMed
  33. Brain. 2009 May;132(Pt 5):1310-23 - PubMed
  34. Nat Med. 2008 Aug;14(8):837-42 - PubMed
  35. Ann N Y Acad Sci. 2004 Jun;1019:1-4 - PubMed
  36. Neurology. 2007 Nov 13;69(20):1911-20 - PubMed
  37. J Neurosci. 2007 Jun 6;27(23):6174-84 - PubMed
  38. Lancet Neurol. 2010 Nov;9(11):1118-27 - PubMed
  39. Neurology. 2009 Jul 28;73(4):294-301 - PubMed
  40. Neurology. 2000 Mar 14;54(5):1109-16 - PubMed
  41. JAMA. 1995 May 3;273(17):1354-9 - PubMed
  42. Alzheimers Dement. 2009 May;5(3):234-70 - PubMed
  43. J Neurosci. 2010 Dec 15;30(50):17035-40 - PubMed
  44. J Neurosci. 2009 Oct 7;29(40):12686-94 - PubMed
  45. Ann Neurol. 2011 Jan;69(1):181-92 - PubMed
  46. Brain. 2007 Nov;130(Pt 11):2837-44 - PubMed
  47. Neurology. 2008 Jul 8;71(2):85-92 - PubMed
  48. Cereb Cortex. 2010 Sep;20(9):2069-79 - PubMed
  49. Neuroepidemiology. 2006;27(3):143-53 - PubMed
  50. Neurology. 1996 Mar;46(3):707-19 - PubMed
  51. Neurology. 2006 Aug 8;67(3):446-52 - PubMed
  52. Neurology. 2006 Jun 27;66(12):1837-44 - PubMed
  53. Alzheimer Dis Assoc Disord. 2005 Jul-Sep;19(3):163-5 - PubMed
  54. Arch Neurol. 2009 Dec;66(12):1476-81 - PubMed
  55. Lancet Neurol. 2010 Jan;9(1):119-28 - PubMed
  56. Biol Psychiatry. 2010 Mar 15;67(6):584-7 - PubMed
  57. Arch Neurol. 2002 Nov;59(11):1737-46 - PubMed
  58. Arch Neurol. 2004 May;61(5):661-6 - PubMed
  59. Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7209-14 - PubMed
  60. Science. 2010 Dec 24;330(6012):1774 - PubMed
  61. Arch Neurol. 2008 Jan;65(1):113-20 - PubMed
  62. Arch Neurol. 2010 Aug;67(8):949-56 - PubMed
  63. Neurology. 1992 Sep;42(9):1681-8 - PubMed
  64. Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):284-9 - PubMed
  65. Alzheimers Dement. 2011 May;7(3):263-9 - PubMed
  66. Am J Public Health. 1998 Sep;88(9):1337-42 - PubMed
  67. Cereb Cortex. 2009 Mar;19(3):497-510 - PubMed
  68. Ann Neurol. 2010 Dec;68(6):825-34 - PubMed
  69. Neuropsychologia. 2009 Aug;47(10):2015-28 - PubMed
  70. Neuron. 2009 Jul 30;63(2):178-88 - PubMed

Substances

MeSH terms

Publication Types

Grant support